Last Updated : September 8, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort ascending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Zytram XL | Tramadol hydrochloride | Pain, acute | Do not list | Complete | ||
Zytram XL | Tramadol hydrochloride | Pain, acute | Withdrawn | |||
Zytiga (Resubmission) | Abiraterone | Prostate Cancer Resubmission | Withdrawn | |||
Zytiga | Abiraterone acetate | Metastatic Castration Resistant Prostate Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Zytiga | Abiraterone | Withdrawn | ||||
Zykadia (Resubmission) | Ceritinib | metastatic non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Zykadia | Ceritinib | Metastatic Non-Small Cell Lung Cancer | Do not reimburse | Complete | ||
Zydelig | Idelalisib | Follicular Lymphoma | Do not reimburse | Complete | ||
Zydelig | Idelalisib | Chronic lymphocytic leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Zoryve | roflumilast | Plaque psoriasis | Reimburse with clinical criteria and/or conditions | Complete |